Phase

Operator

Operated by BioBM

For providers

Claim your profile Pricing & sponsorship How rankings work

Site

About Privacy Cookie preferences TermsTransparency

Cookies and analytics

We use essential cookies to run the site and Cloudflare Web Analytics (privacy-first, no advertising cookies) for traffic and performance. With your permission we also load Google Analytics 4. We never sell your information, and we do not use it for advertising or ad personalization. You can change the GA4 choice anytime under Cookie preferences.

Search CROs | cro.directory

Search CROs

5 results for “Rapid Novor Inc.”

Sort by

Filters

Phases

Discovery
Preclinical (General)
Preclinical (IND-Enabling)
Phase 0 (Exploratory IND)
Phase I
Phase II
Phase III
Phase IV
Real-World Evidence (RWE) / Registries

Modalities

AAV / Viral Vector Platform
Antibody-Drug Conjugate (ADC)
Biologics (Monoclonal Antibodies)
Biologics (Other)
Cell Therapy
Gene Therapy
Microbiome Therapeutic
Oligonucleotide
Peptide
Radiopharmaceutical
Small Molecule
Synthetic Biology
Vaccine
mRNA

Locations

Regions

United States
Canada
Europe
Asia-Pacific
Latin America
Middle East
Africa

Countries

Afghanistan
Åland Islands
Albania
Algeria
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong SAR China
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao SAR China
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
North Macedonia
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russia
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Türkiye
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Kingdom
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe

Services

Analytical Method Development & Validation
Bioanalysis
Bioinformatics & Data Science
Biomarker Assays
Biostatistics & Statistical Programming
CNS Specialty Services
Carcinogenicity Studies
Cardiovascular & Metabolic Specialty Services
Central Laboratory Services
China NMPA Regulatory Strategy
Clinical Imaging Core Lab
Clinical Operations
Clinical Trial Services
Companion Diagnostics Development
Computational & In-Silico Drug Discovery
DART (Reproductive & Developmental Toxicology)
Data Management & eClinical
Device & Combination Product Services
Discovery Research
EU EMA Regulatory Strategy
Flow Cytometry Services
GLP Toxicology
Genetic Toxicology
Genomics & Sequencing Services
High-Throughput Screening
ICH Stability Studies
Immunogenicity Assays (ADA / NAb)
Immunology & Inflammation Services
In Vitro ADME / DMPK
In Vitro Pharmacology
In Vivo Efficacy Models
In Vivo PK / PD Studies
Japan PMDA Regulatory Strategy
LC-MS Bioanalysis (Small Molecule)
Ligand-Binding Bioanalysis (Large Molecule)
Medical Writing
Medicinal Chemistry
Microbiology Services
Oncology Specialty Services
Pathology & Histology Services
Pharmacovigilance & Drug Safety
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV / Post-Marketing
Preclinical In Vitro Studies
Preclinical In Vivo Studies
Protein Engineering
Proteomics Services
Regulatory Affairs
Safety Pharmacology
Specialized & Large-Animal Models
Target Identification & Validation
Translational Research
US FDA Regulatory Strategy
Virology Services

Accreditations

AAALAC accredited
GLP compliant
GCP compliant
GMP compliant
CLIA certified
CAP accredited

Infrastructure

In-house central labs
In-house bioanalytical labs
Core labs — imaging / cardiac

Sourcing Model

Full-Service Outsourcing (FSO)
Functional Service Provider (FSP)

Reviews

Has reviewsMin overall rating

Review-based filters and average ratings stay secondary until the directory-wide review signal gate opens (see how reviews work). Result averages are hidden in listings until then.

Rapid Novor Inc.
- Discovery Research
- Protein Engineering
- Proteomics Services
Rapid Novor provides antibody discovery, sequencing, and characterization services powered by mass spectrometry, including de novo sequencing, HDX-MS epitope mapping, and surface plasmon resonance analysis.
Qoolabs, Inc
- Protein Engineering
- Translational Research
- Biologics (Monoclonal Antibodies)

Filters

Phases

Discovery
Preclinical (General)
Preclinical (IND-Enabling)
Phase 0 (Exploratory IND)
Phase I
Phase II
Phase III
Phase IV
Real-World Evidence (RWE) / Registries

Modalities

AAV / Viral Vector Platform
Antibody-Drug Conjugate (ADC)
Biologics (Monoclonal Antibodies)
Biologics (Other)
Cell Therapy
Gene Therapy
Microbiome Therapeutic
Oligonucleotide
Peptide
Radiopharmaceutical
Small Molecule
Synthetic Biology
Vaccine
mRNA

Locations

Regions

United States
Canada
Europe
Asia-Pacific
Latin America
Middle East
Africa

Countries

Afghanistan
Åland Islands
Albania
Algeria
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong SAR China
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao SAR China
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
North Macedonia
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russia
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Türkiye
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Kingdom
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe

Services

Analytical Method Development & Validation
Bioanalysis
Bioinformatics & Data Science
Biomarker Assays
Biostatistics & Statistical Programming
CNS Specialty Services
Carcinogenicity Studies
Cardiovascular & Metabolic Specialty Services
Central Laboratory Services
China NMPA Regulatory Strategy
Clinical Imaging Core Lab
Clinical Operations
Clinical Trial Services
Companion Diagnostics Development
Computational & In-Silico Drug Discovery
DART (Reproductive & Developmental Toxicology)
Data Management & eClinical
Device & Combination Product Services
Discovery Research
EU EMA Regulatory Strategy
Flow Cytometry Services
GLP Toxicology
Genetic Toxicology
Genomics & Sequencing Services
High-Throughput Screening
ICH Stability Studies
Immunogenicity Assays (ADA / NAb)
Immunology & Inflammation Services
In Vitro ADME / DMPK
In Vitro Pharmacology
In Vivo Efficacy Models
In Vivo PK / PD Studies
Japan PMDA Regulatory Strategy
LC-MS Bioanalysis (Small Molecule)
Ligand-Binding Bioanalysis (Large Molecule)
Medical Writing
Medicinal Chemistry
Microbiology Services
Oncology Specialty Services
Pathology & Histology Services
Pharmacovigilance & Drug Safety
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV / Post-Marketing
Preclinical In Vitro Studies
Preclinical In Vivo Studies
Protein Engineering
Proteomics Services
Regulatory Affairs
Safety Pharmacology
Specialized & Large-Animal Models
Target Identification & Validation
Translational Research
US FDA Regulatory Strategy
Virology Services

Accreditations

AAALAC accredited
GLP compliant
GCP compliant
GMP compliant
CLIA certified
CAP accredited

Infrastructure

In-house central labs
In-house bioanalytical labs
Core labs — imaging / cardiac

Sourcing Model

Full-Service Outsourcing (FSO)
Functional Service Provider (FSP)

Reviews

Has reviewsMin overall rating

Qoolabs specializes in rapid rabbit monoclonal antibody development using the QMAb™ platform, delivering highly specific antibodies with natural heavy-light chain pairing in 3–4 months from immunization.

PharPoint Research

Biostatistics & Statistical Programming
Clinical Operations
Phase I Clinical Trials

PharPoint is a US-based CRO specializing in Phase I–IV clinical trials with rapid biometrics timelines, delivering database locks within 5 days of last patient visit and topline results in 2 business days.

Clutch Biotechnologies, Inc.

Discovery Research
Translational Research
Synthetic Biology

ClutchBio provides plasmid cloning services and modular DNA design platforms for research teams with high cloning needs and rapid iteration cycles.

Fog City Bio

Analytical Method Development & Validation
Bioanalysis
Biomarker Assays

Specialized CRO for custom immunoassay development using Simoa, HTRF, AlphaLISA, Luminex, MSD ECL, and other platforms. Direct scientist communication with rapid optimization workflows.

Showing 1–5 of 5

Results per page

Search CROs

Sponsored